Murine Monoclonal Antibodies Effective To Treat Respiratory Syncytial Virus
Posted Feb 13 2013 7:00pm
Description of Invention: Available for licensing through a Biological Materials License Agreement are the murine MAbs described in Beeler et al, "Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function," J Virol. 1989 Jul;63(7):2941-2950 ( PubMed abs ). The MAbs that are available for licensing are the following: 1129, 1153, 1142, 1200, 1214, 1237, 1112, 1269, and 1243. One of these MAbs, 1129, is the basis for a humanized murine MAb (see U.S. Patent 5,824,307 to humanized 1129 owned by MedImmune, Inc.), recently approved for marketing in the United States. MAbs in the panel reported by Beeler et al. have been shown to be effective therapeutically when administered into the lungs of cotton rats by small-particle aerosol. Among these MAbs several exhibited a high affinity (approximately 109M-1) for the RSV F glycoprotein and are directed at epitopes encompassing amino acid 262, 272, 275, 276 or 389. These epitopes are separate, nonoverlapping and distinct from the epitope recognized by the human Fab of U.S. Patent 5,762,905 owned by The Scripps Research Institute.
Applications: Research and drug development for treatment of respiratory syncytial virus
Inventors: Brian R Murphy (NIAID) Robert M Chanock (NIAID) Judith A Beeler (NIAID) Kathleen L Coelingh (NIAID) Peter L Collins (NIAID)
Patent Status: HHS, Reference No. B-056-1994/1
Research Material -- Patent protection is not being pursued for this technology
Licensing Status: Available for non-exclusive licensing under a Biological Materials License Agreement.
For Licensing Information Please Contact: Peter Soukas J.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 14, Rockville, MD 20852-3804 United States Email: email@example.com Phone: 301-435-4646 Fax: 301-402-0220